Insulet stock holds near its yearly low as Q1 growth leads

Published on 09/23/2026 at 13:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insulet stock traded at USD 140.53 on September 22, 2026, 10.1 percent above its yearly low. Q1 revenue rose 33.9 percent to USD 761.7 million.

Flatlay Insulet – Aktienzertifikat, ISIN-Karte US45784P1012, Pod-Gerät und Stethoskop auf Marmor — Insulet Aktien-Flatlay auf weißem Marmor mit Börsenzertifikat, ISIN-Karte US45784P1012, Insulin-Pod und Stethoskop, Illustration mit AI erstellt.

Insulet Corporation (ISIN US45784P1012) closed at USD 140.53 on Nasdaq on September 22, 2026, just 10.1 percent above its 52-week low of USD 126.40 and well below the 52-week high of USD 354.88. The stock's position near the lower end of its annual range gives the latest operating figures particular weight.

Q1 revenue rose 33.9 percent

According to Stock Titan, Insulet reported revenue of USD 761.7 million in Q1 2026, up 33.9 percent from the year-earlier period. Omnipod product revenue increased 36.9 percent in the same quarter, making product growth the clearest operating comparison in the available figures.

Net income reached USD 91.1 million in Q1 2026, while diluted earnings per share came to USD 1.30. Operating cash flow was USD 113.8 million and free cash flow was USD 89.5 million, giving the quarter a stronger cash-generation profile than the earnings figure alone suggests.

Margin pressure offsets expansion

The counter-factor was profitability quality: gross margin stood at 69.5 percent in Q1 2026, with inventory reserves and warranty costs linked to a voluntary Omnipod 5 medical device correction weighing on the result. The combination of 33.9 percent revenue growth and a 69.5 percent gross margin leaves execution and product-cost control as the central operating test.

Insulet ended Q1 2026 with USD 480.4 million in cash and USD 948.1 million in net debt, according to Stock Titan. The company also repurchased USD 300 million of stock under accelerated share repurchase agreements, a capital-allocation figure that contrasts with the debt position and adds a second variable for investors assessing the shares.

Stock remains near annual low

On September 22, 2026, Insulet stock was USD 14.13, or 10.1 percent, above its 52-week low and USD 214.35 below its 52-week high. Moneycontrol showed a USD 9.75 billion market capitalization on September 23, 2026, while its intraday quote was USD 140.53 and the daily change was minus 0.05 percent at the Nasdaq close shown by Yahoo Finance.

Insulet stock therefore combines a dated market value near the bottom of its annual range with recent double-digit operating growth. The key comparison is not revenue growth alone: Q1 2026 free cash flow of USD 89.5 million must be weighed against the 69.5 percent gross margin and USD 948.1 million of net debt.